From the Research
Mounjaro (tirzepatide) can cause elevated liver enzymes in some patients, although this side effect is considered uncommon and typically mild to moderate, often resolving without discontinuation of the medication. The elevations are usually transient, and patients with pre-existing liver disease may be at higher risk for this side effect 1. Regular monitoring of liver function tests is recommended when starting Mounjaro, particularly during the first few months of treatment. If a patient develops symptoms such as right upper abdominal pain, nausea, vomiting, fatigue, or yellowing of the skin or eyes while taking Mounjaro, they should contact their healthcare provider immediately as these could indicate liver problems.
Some key points to consider:
- The mechanism behind tirzepatide's effect on liver enzymes is not fully understood but may relate to its metabolic effects or direct impact on liver cells through GLP-1 and GIP receptor activation 2.
- Most patients can continue treatment with appropriate monitoring, but in cases of significant enzyme elevation, dose reduction or medication discontinuation might be necessary 3.
- Tirzepatide has been shown to reduce liver fat content and abdominal adipose tissue in people with type 2 diabetes, which could have a positive impact on liver health 4.
- The safety profile of tirzepatide is consistent with that of GLP-1 receptor agonists, with a low risk of clinically significant or severe hypoglycaemia and no increased risk of major adverse cardiovascular events 1.
Overall, while Mounjaro can cause elevated liver enzymes in some patients, the benefits of treatment often outweigh the risks, and regular monitoring can help mitigate this side effect.